

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : G01N 33/68, 33/00, C07K 15/06 C12Q 1/56	A1	(11) International Publication Number: WO 93/07491
		(43) International Publication Date: 15 April 1993 (15.04.93)

(21) International Application Number: PCT/US92/08389	(81) Designated States: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG).
(22) International Filing Date: 2 October 1992 (02.10.92)	
(30) Priority data: 771,644 4 October 1991 (04.10.91) US	
(71) Applicant: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA [US/US]; Regents Hall, Lincoln, NB 68583-0745 (US).	Published <i>With international search report.</i>
(72) Inventor: MATSCHINER, John, T. ; 3554 Davenport, Omaha, NB 68131 (US).	
(74) Agent: FLOYD, John, P.; 200 Roger Webster, Williamsburg, VA 23185 (US).	

(54) Title: A SOLUBLE THROMBOMODULIN-BASED ONE-STAGE ASSAY FOR VITAMIN K-DEPENDENT COAGULATION-INHIBITING PROTEINS

(57) Abstract

The present invention provides a novel one-stage assay which uses soluble thrombomodulin for directly determining the functional status in plasma of the vitamin K-dependent coagulation-inhibiting proteins, protein C and protein S. The method comprises combining a blood plasma test sample and a coagulation-activating substance in a calcium-free solution, then adding soluble thrombomodulin and calcium ions to initiate a coagulation reaction, measuring the time required for the test plasma sample to clot, comparing the measured clot time to that of standard control plasma samples, including protein C- and protein S-deficient plasma controls, and then using the compared clot time values for determining the functional status of protein C and protein S in the individual from whom the test plasma sample was taken. The functional status of the vitamin K-dependent coagulation-inhibiting proteins is used to determine the risk of thrombosis in the host individual.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SK	Slovak Republic
CI	Côte d'Ivoire	LK	Sri Lanka	SN	Senegal
CM	Cameroon	LU	Luxembourg	SU	Soviet Union
CS	Czechoslovakia	MC	Monaco	TD	Chad
CZ	Czech Republic	MG	Madagascar	TG	Togo
DE	Germany	ML	Mali	UA	Ukraine
DK	Denmark	MN	Mongolia	US	United States of America
ES	Spain			VN	Viet Nam
FI	Finland				

WO 93/07491

PCT/US92/08389

-1-

A SOLUBLE THROMBOMODULIN-BASED ONE-STAGE ASSAY FOR VITAMIN
K-DEPENDENT COAGULATION-INHIBITING PROTEINS

FIELD OF THE INVENTION

The present invention relates to a novel one-stage blood coagulation assay which incorporates soluble thrombomodulin for the rapid and direct *in vitro* determination of the functional status of vitamin K-dependent coagulation-inhibiting proteins in a plasma sample. In particular, the functional status of protein C and protein S are reliably and sensitively determined with this assay, without separation from the plasma sample in which they are contained. In addition, the present invention relates to novel molecular complexes produced in the aforementioned one-stage blood coagulation assay.

15

BACKGROUND AND OBJECTS OF THE PRESENT INVENTION

The capacity of blood to clot and stop flowing from a wound is dependent on the proper functional interaction of a large number of factors and cofactors in the blood coagulation cascade. The ability of clinical laboratories to reliably and conveniently assay for these factors and cofactors in plasma samples from donor patients can be critical in monitoring individuals for whom either inappropriate coagulation episodes (such as occurs, for example, in disseminated intravascular coagulation disease) or inappropriate failure of blood to clot (such as occurs, for example, in hemophilia) is a daily life-threatening problem.

The physiologic basis for these clinically important coagulation problems can be exceedingly complex to diagnose. In most cases, however, diagnosis can be made by detecting either quantitative or functional changes in certain of the biological factors and cofactors which activate or regulate the coagulation process. A number of diagnostic assays have been developed which reliably measure many of the regulatory proteins involved in the coagulation cascade (see, for example, the textbooks by R. Hoffman et al., Hematology: Basic Principles and Practice, New York: Churchill Livingston Inc., 1991; and by C. Kjeldsberg et al., Practical Diagnosis of Hematologic Disorders, Chicago: American Society of Clinical Pathologists Press, 1989). These include such routine coagulation assays as the activated partial thromboplastin time (APTT) assay, the prothrombin time (PT) assay, and the thrombin clotting time (TCT) assay. In spite of extensive research, none of these assays directly measure, in a one-stage assay, the functional status in plasma of the vitamin K-dependent coagulation-inhibiting proteins, protein C and protein S. Because protein C and protein S are both essential in the normal regulatory process of down-regulating the blood coagulation cascade, the lack of any one-stage assay which directly determines both of their functional activities remains a serious deficiency in the art.

25 The need for a convenient one-stage assay for determining protein C and protein S function in plasma is emphasized by the fact that abnormalities in protein C and protein S function are

more common in the population than is usually believed. For example, from 4-to-5% of the population as a whole have genetically-acquired protein C or protein S deficiencies, and a large number of these individuals have a clinical history of recurrent thrombotic (microvascular clotting) episodes (Gladson et al., Thromb. Haemostas. 59: 18, 1988). It is these individuals who should be regularly monitored for the functional activities of these coagulation-inhibiting proteins. Individuals who are known to be at high risk for recurrent thrombosis (which can be lethal) should be kept on lifelong maintenance anticoagulant therapy, with regular monitoring.

The coagulation enzyme system

To better appreciate the importance of such assays, and how activated protein C and protein S are involved in regulating the blood coagulation cascade, the following brief description of the coagulation enzyme system is provided.

The blood clotting system may best be viewed as a chain reaction involving the sequential activation of inactive enzyme precursors (zymogens) into active serine proteases. These activation events, which take place on the surfaces of cells such as platelets, white blood cells, and endothelial cells, have been divided into two distinct pathways termed the extrinsic and the intrinsic pathways of coagulation. A clot is generated in the intrinsic pathway by activation of those coagulation components which are all contained in (or are

"intrinsic to") whole blood. In the extrinsic pathway, components intrinsic to whole blood are required along with an externally-supplied coagulation-activating substance known as "tissue factor" (also sometimes referred to as thromboplastin, 5 thrombokinase, or blood coagulation factor III). Tissue factor is a cell surface protein extrinsic to blood, and is expressed by cellular injury. Whether a particular coagulation factor becomes activated in the extrinsic or the intrinsic pathway is important in selecting a particular coagulometric assay with 10 which to detect and evaluate that particular factor.

Thrombin. The multistep coagulation chain reaction ultimately produces the enzyme thrombin, the last serine protease in the coagulation cascade, which, through limited 15 proteolysis, converts fibrinogen molecules into an insoluble gel of fibrin fibers which forms the physical clot. Two key events in the coagulation cascade are the conversion of clotting factor X into an activated form, factor Xa, and the subsequent conversion of prothrombin by factor Xa into thrombin. Both of 20 these conversion reactions occur on cell surfaces, such as, for example, the surfaces of platelets, and both reactions require cofactors. These cofactors, factors V and VIII, are in circulation in the form of relatively inactive precursor molecules. When the first few molecules of thrombin are formed, 25 thrombin loops back and activates factors V and VIII through limited proteolysis. The activated factors, Va and VIIIa, accelerate both the conversion of prothrombin into thrombin and

also the conversion of factor X to factor Xa, speeding the clotting process by approximately 100,000 fold. This significant amplification is essential in the timely formation of a clot. As will be discussed below, factors Va and VIIIa are 5 the principal protein targets of activated protein C and protein S.

Thrombomodulin. Some of the thrombin formed during the formation of a clot is also bound by thrombomodulin, an 10 essential reagent used in soluble form in the present invention. Thrombomodulin is a glycoprotein normally found fixed in the surface membranes of endothelial cells that form the lining of all blood vessels. While vascular endothelium once was thought to be a passive barrier which simply channeled the blood, it now 15 is known that endothelial cells are actively involved in the regulation of intravascular coagulation mechanisms, and that much of this activity is due to the thrombomodulin in the endothelial cell membranes.

20 Thrombin-thrombomodulin complex. Thrombomodulin forms a tight, stoichiometric complex with thrombin, altering both the physical shape and functional properties of thrombin so that it no longer has procoagulant activity, i.e., it no longer converts fibrinogen to fibrin, activates platelets, or converts clotting 25 factors V and VIII to their activated counterparts Va and VIIIa. Rather, the thrombin which is bound by thrombomodulin becomes an efficient activator of protein C. The rate constant for the

activation of protein C by thrombin bound in a thrombomodulin-thrombin complex is ~~nearly 10,000~~^{about 20,000} fold higher than the rate constant for activation of protein C by thrombin found free in solution. Additionally, activation of protein C by thrombin in 5 the absence of thrombomodulin is inhibited by calcium ions, whereas activation by the thrombin/thrombomodulin complex is a calcium-dependent reaction.

Thus, the coagulation-inhibiting effects of thrombomodulin 10 are of two different types. One is a heparin-like anticoagulant effect, in which the binding of thrombin to thrombomodulin inhibits the capacity of thrombin to enzymatically convert fibrinogen into fibrin fibers; the anticoagulant heparin exerts a similar antithrombin effect. This is the thrombomodulin-mediated anticoagulant effect most commonly observed by others 15 (for example, see Gomi et al., Blood 75: 1396, 1990).

The second anticoagulant effect of thrombomodulin results from the activation of protein C by the thrombin-thrombomodulin 20 complex. This effect is the key component of the present invention. When activated, protein C has the capacity to enzymatically cleave (via hydrolysis) both factor Va and factor VIIIa, substantially inhibiting both of their clot-promoting activities. In the presence of its vitamin K-dependent cofactor 25 protein S, the rate of activated protein C-mediated hydrolysis of factors Va and VIIIa is increased by about 25 fold compared to hydrolysis in the absence of protein S. Thus, one of the

important mechanisms operating in the vascular endothelium to maintain the normal anticoagulant state of the endothelial surface is the pathway by which a thrombin-thrombomodulin complex activates protein C to form a coagulation-inhibiting activated protein C-protein S complex on a cell surface.

The vitamin K-dependency of the protein C and protein S coagulation-inhibiting proteins derives from the fact that a vitamin K-dependent microsomal carboxylase enzyme in the liver forms an unusual amino acid, gammacarboxyglutamic acid, in a post-ribosomal carboxylation step in the precursor proteins of both protein C and protein S. The appearance of the gammacarboxyglutamic acid moieties in these protein molecules is crucial in that it facilitates their efficient binding, via a calcium-mediated bridge, to phospholipid-containing surfaces such as, for example, the surfaces of platelets, endothelial cells, and, importantly for *in vitro* coagulometric assays, phospholipid micelles in solution. As noted below, the binding of the carboxylated glycoproteins to a phospholipid surface allows the proteins to concentrate, interface and interact with one another more efficiently in three-dimensional space. Several *in vitro* clotting assays take advantage of this fact, in that phospholipids are included among the necessary reagents used in the coagulometric assays.

25

Phospholipid. All clotting reactions with meaningful rates are viewed as occurring on a surface. Crucial to the efficient

interaction of thrombomodulin (the cofactor), thrombin (the enzyme), and protein C (the substrate) is the presence of calcium ions and an integrating surface such as is found, for example, on a soluble phospholipid micelle (a submicroscopic phospholipid sphere). On such a surface, the three reactants are brought into close proximity, thereby substantially increasing their effective concentrations and their reaction rate many fold. It is believed that all relevant soluble complexes which contain soluble thrombomodulin, thrombin and activated protein C, and which produce vitamin K-dependent anticoagulant activity, also contain an essential surface component. The *in vitro* clotting assays of the present invention take advantage of this fact by the use of a suitable phospholipid (cephalin) in a preferred embodiment.

15

Protein C and Protein S assays

Until the present invention, it has not been possible to conveniently measure the functional activities of both protein C and protein S in a simple and rapid one-stage *in vitro* assay. This is because soluble thrombomodulin has never before been added directly into laboratory coagulometric assays to detect protein C zymogen. Rather, thrombomodulin has been added with thrombin as a preactivation reagent, either as a soluble complex, or in an immobilized form and in conjunction with a process which required either prior separation of protein C from other plasma components or the subsequent removal of activated protein C from other plasma components in order to carry out the

final determination of activated protein C in a separate coagulometric amidolytic assay. Thus, the anticoagulatory effect of soluble thrombomodulin, in the form of soluble thrombomodulin-thrombin complexes, has never been exploited 5 directly in conventional clinical assays.

Protein C assays

For protein C, a number of different assays are available for its determination (as reviewed in detail by Löbermann et al., Behring Inst. Mitt. 79:112, 1986; Vigano-D'Angelo et al., 10 in Biotechnology in Clinical Medicine [Albertini et al., editors] New York: Raven Press, 1989; and more recently by Preissner, Clin. Sci. 78: 351, 1990). The assays generally fall into three categories: antigenic detection assays, chromogenic 15 (amidolytic) assays, and functional coagulometric assays.

Protein C antigenic assays. For determination of protein C antigen concentration in plasma, detection assays include electroimmunoassay, radioimmunoassay, and ELISA-type assays. Not only polyclonal antibodies from rabbit or goat, but also 20 monoclonal antibodies have been used as detecting reagents in these assays. While *in vitro* detection of protein C with antibodies is a sensitive procedure, antigenic detection provides little or no information regarding the functional 25 capacity of the protein C detected.

Protein C chromogenic assays. Alternatively, because activated protein C is an enzyme, its presence in a plasma sample can be quantified with a chromogenic substrate. Prior activation of protein C, with exposure of the enzymatic active site, is required for expression of its enzymatic activity. However, the relatively small size of the synthetic chromogenic substrate (about 600 daltons) commonly used in these assays may permit satisfactory proteolysis of the synthetic substrate, while missing defects in the functional integrity of protein C which would prevent proteolytic cleavage of factor Va and VIIIa, the biological substrates of activated protein C which each have molecular weights of about 300,000 daltons. Moreover, the interaction of activated protein C with its cofactors (protein S, calcium ions, and phospholipid), which requires that all functional features of the protein C molecule be intact, is not evaluated by chromogenic assays. It is important to be aware of this, since protein C molecules detected in chromogenic assays can still be deficient in functional anticoagulant capacity.

Protein C coagulometric assays. For determination of functional capacity of protein C molecules in a plasma sample, coagulometric assays offer the advantage of evaluating the coagulation-inhibiting activity of activated protein C in the presence of its usual biological substrates and cofactors, thereby reflecting more accurately the physiologic state of the protein C in the particular plasma sample being evaluated.

The protein C in a plasma sample is commonly activated before it is assayed. This activation is done either with or without prior separation of protein C from other plasma components. Isolation of the protein C from the test plasma sample has (up until the present invention) been necessary if the protein C is to be activated by thrombin or by the physiological activator, which is the thrombin/thrombomodulin complex. Unfortunately, because of poor reaction kinetics, activation of protein C with thrombin in the absence of thrombomodulin does not lead to complete activation of protein C in the sample. In contrast, when thrombin is bound to thrombomodulin, the rate of activation is increased by about 20,000 fold over the rate obtained with thrombin alone.

Activation can also be carried out without prior isolation of protein C from the test plasma sample by use of a snake venom activator such as, for example, southern copperhead venom, or the "PROTAC[®] C" reagent (the latter from Pentapharm, Basel, Switzerland).

20

After either of the above procedures, the anticoagulant activity of activated protein C is assessed most commonly either by prolongation of the otherwise routine activated partial thromboplastin time (APTT) assay, or in a factor Xa one-stage coagulometric assay. The clot time in this latter assay is a function of the conversion of prothrombin to thrombin, and is initiated by the addition of exogenous factor Xa to the plasma

sample in the presence of calcium ions and a phospholipid component. The assay is sensitive to activated factor V, but not to activated factor VIII. In this system, addition of preactivated protein C from the test plasma sample to a control plasma sample prior to the addition of factor Xa prolongs the clot time as a result of its ability to inactivate factor Va generated during the reaction.

In stark contrast to the commonly used assays discussed above, the novel assay of the present invention does not require preliminary isolation of protein C from a plasma test sample; it permits the activation of protein C with its physiological activator, the thrombin/thrombomodulin complex; and it results in a determination of protein C functional activity in the test sample, all in a simple one-stage procedure.

Protein S assays

Laboratory evaluation of protein S status is complicated by the fact that two forms of protein S are present in plasma. In plasma, about 40% to 50% of the protein S is free and serves as the cofactor for activated protein C. The remaining 50% to 60% of plasma protein S is complexed to C4b binding protein ("C4bBP") and, as such, is unavailable as an anticoagulant. That C4bBP is an acute phase protein and is elevated during inflammation further complicates evaluation of protein S status. This rise in C4bBP favors a transient shift of the protein S to the complexed form, thereby inducing a relative and transient

protein S deficiency state. Because protein S which is bound to C4bBP in plasma is no longer able to function as a cofactor with activated protein C, individuals with serious inflammatory disorders are often at risk for thrombosis. This is an acquired situation which will rise and fall, and even disappear, depending on the state of the inflammatory disorder.

In the clinical laboratory, a very limited number of tests are available to assess protein S status, and these are generally antigen detection assays. These tests include polyethylene glycol precipitation of bound protein S with subsequent measurement of the free protein S remaining in the plasma; crossed immunoelectrophoresis for protein S, which separates free and bound forms of protein S but is not quantitative; and enzyme-linked immunosorbent assays (ELISA). ELISA assays are suitable in combination with PEG precipitation to quantitate free protein S. However, while ELISA assays may detect protein S with sensitivity, such antigen detecting assays provide little or no information regarding the functional capacity of the protein S detected. Unfortunately, standardized functional assays for protein S are not yet available in the general clinical laboratory.

It is, therefore, a principal object of the present invention to provide a convenient and reliable one-stage assay by which both of the vitamin K-dependent coagulation-inhibiting proteins, protein C and protein S, can be quantitatively and

functionally determined in a blood plasma test sample in a clinical laboratory.

It is another object of the present invention to provide a
5 soluble coagulation-inhibiting complex comprising soluble thrombomodulin, thrombin and protein C, bound to a soluble phospholipid surface. Such a phospholipid surface is found, for example, on soluble phospholipid micelles.

10 It is still another object of the present invention to provide a soluble complex comprising activated protein C and its cofactor, protein S, bound to a soluble phospholipid surface.

15 Yet another object is to provide a soluble complex comprising activated protein C, protein S and factor Va bound to a soluble phospholipid surface.

Still another object is to provide a soluble complex comprising activated protein C, protein S and factor VIIIa bound
20 to a soluble phospholipid surface.

SUMMARY OF THE PRESENT INVENTION

In accordance with the present invention, there is provided
25 a novel one-stage assay which uses soluble thrombomodulin for determining in a novel blood coagulation assay the functional status of vitamin K-dependent coagulation-inhibiting proteins in

plasma. The method comprises combining a blood plasma sample and a coagulation-activating substance in a calcium-free solution, then adding soluble thrombomodulin and calcium ions in amounts sufficient to initiate a coagulation reaction, measuring 5 the time required for the plasma test sample to clot, comparing the measured clot time to that of standard control plasma samples, and then using the compared clot time values for determining the risk of thrombosis in the individual from whom the plasma test sample was taken.

10

In a preferred embodiment of the present invention, soluble thrombomodulin is added simultaneously with the calcium ions (i.e., the recalcification step), and the subsequent extension of the clot time caused by the anticoagulant effect of the 15 soluble thrombomodulin is compared to the extension of clot time that is observed in protein C- and/or protein S-deficient plasma samples used as deficient plasma controls.

The vitamin K-dependent coagulation inhibiting factors with 20 which the present invention is principally concerned are protein C and protein S, both of which are essential regulatory factors in maintaining the anticoagulatory state of the endothelial cell lining of all blood vessels in the body. Any other coagulation-inhibiting protein, the functional status of which may be 25 determined in these assays by using the methods taught herein, are also included within the scope of the present invention.

The coagulation-activating substance added to the mix of reagents at the beginning of the assay of this invention is, in the preferred embodiment, the "DADE[®]/ACTIN[®] ACTIVATED CEPHALOPLASTIN REAGENT". This reagent is available commercially from the Baxter Healthcare Corporation and is more fully described in its package insert No. L10293-BH-H (revised 10/88) (Baxter/Dade, Miami, FL), the content of which is incorporated herein by reference. The coagulation-activating ingredient in this reagent is ellagic acid, a negatively-charged organic compound of formula C₁₄H₈O₆, having a molecular weight of about 302 daltons.

In another embodiment, the coagulation-activating substance is factor Xa. Factor Xa acts upon prothrombin in the presence of factor V, calcium ions and phospholipid to form a complex which activates prothrombin, converting it to thrombin.


In another embodiment, the coagulation-activating substance is a reptilase, preferably, Russell's viper venom, which is available from a variety of commercial sources. Russell's viper venom is an activator of factor X, enzymatically cleaving factor X to generate factor Xa, which is the procoagulant factor just discussed.

In yet another embodiment, the coagulation activating substance is a protein known as "tissue factor", which is a cell surface protein released into blood following cellular damage.

Tissue factor is a membrane receptor for factor VII, and is available from a variety of commercial sources. In conjunction with tissue factor and calcium ions, factor VII enzymatically modifies factor X, converting factor X to its procoagulant form,
5 factor Xa, discussed above.

In still other embodiments, coagulation activating substances include negatively-charged collagen molecules; or negatively-charged foreign surfaces such as micronized silica,
10 kaolin, fine glass or metal beads, and even wooden applicator sticks. The use of these latter particulates are limited, however, to assays in which the presence of such insoluble foreign surfaces will not interfere in carrying out the assay.

15 In the preferred embodiment of the present invention, the phospholipid added to the assay is cephalin, a glycerophosphoric acid extracted from dehydrated rabbit brain, and contained as an active ingredient in the "DADE®/ACTIN® ACTIVATED CEPHALOPLASTIN REAGENT", as more fully described in the Baxter Healthcare
20 Corporation package insert No. L10293-BH-H [revised 10/88] (Baxter/Dade, Miami, FL). Biochemically, cephalins consist of glycerophosphoric acid in which the two free hydroxyls of the molecule are esterified with long-chain fatty acid residues, and ethanolamine forms an ester linkage with the phosphate group.
25 All natural cephalin products occur in alpha-forms, which have the following generic structure:



where R and R' can be, but are not necessarily, identical fatty acids.

15

Other phospholipids which may be used in further embodiments of the present invention are those which successfully facilitate the activation of protein C and its detection in the coagulometric assays of the present invention.

20 It is believed that all relevant soluble complexes which contain
soluble thrombomodulin, thrombin and activated protein C, and
which produce vitamin K-dependent anticoagulant activity, also
contain an essential surface component. The in vitro clotting
assays of the present invention take advantage of this fact by
25 the use of a suitable phospholipid (cephalin) in a preferred
embodiment. However, besides phospholipids, any micelle-forming
(or liposome-forming) ingredient which is amphipathic and whose
charge distribution and size make it optimal for use as a
surface carrier in facilitating the coagulometric assays
30 disclosed in the present invention is included within the scope
of the coagulation-activating agents of the present invention.

By the term "normal control plasma" as used above and hereinafter is meant a plasma sample which contains the usual (statistically common) and expected amounts of all known coagulation-related factors which are essential in promoting the clotting of plasma by either the intrinsic or the extrinsic coagulation pathways. Such factors are known to those skilled in the art, and usual (statistically common) values, with normal range of values, are to be found in such well-known textbooks as that by C. Kjeldsberg et al., Practical Diagnosis of Hematologic Disorders, Chicago: American Society of Clinical Pathologists Press, 1989. It is also standard practice in the art to combine plasma samples from a large number of normal, healthy volunteer donors to generate a larger "pooled" batch of normal plasma. The advantage of such a pool is that normal plasma samples with identical control values will be available over a long period of time, especially if such standardized control samples are preserved in a frozen or lyophilized (freeze-dried) state.

The term "test sample" or "plasma test sample" as used above and hereinafter simply refers to a plasma sample in which the protein C or protein S content are not yet known, and which is the subject of the coagulometric assay.

It is to be understood that any of the preferred assays of the present invention, when properly set up, can be used to detect the presence or the functional activity of the coagulation-inhibiting proteins, protein C and protein S in a

plasma sample; i.e., they can be used to detect or to measure protein C and/or protein S qualitatively or quantitatively, respectively. Thus, the terms "detect" and "detecting", "measure" and "measuring", and "determine" and "determining" as used above and hereinafter are meant to cover both the quantitative and the qualitative aspects of the assays.

In accordance with the present invention, there are also provided several molecular complexes which are novel compositions of matter produced by the process of the assay itself. To the best of our knowledge, the existence of these soluble complexes has never before been described. In preferred embodiments of the present invention, these soluble complexes include the following:

15

- 1) soluble thrombomodulin, thrombin and protein C bound to a soluble phospholipid surface;
- 2) activated protein C and protein S bound to a soluble phospholipid surface;
- 20 3) activated protein C, protein S and factor Va bound to a soluble phospholipid surface; and
- 4) activated protein C, protein S and factor VIIIa bound to a soluble phospholipid surface.

25

BRIEF DESCRIPTION OF THE DRAWINGS

FIGURE 1 is a line graph which demonstrates that inclusion of soluble thrombomodulin in a coagulometric assay has a significantly different anticoagulant effect on a protein C-deficient plasma sample than it does on a normal control plasma sample. The final amount of soluble thrombomodulin (in micrograms) added to the assay is plotted versus clot time (in seconds) for each sample mixture. The curve with filled circles (●) represents the normal control plasma, and the open circles (○) represent the protein C-deficient plasma.

10

FIGURE 2 shows the results of coagulometric assays in which protein S and protein C functional activity are determined using the same methodological embodiment of the present invention. The concentration of normal plasma used to dilute each of the protein C- and protein S-deficient plasma samples is plotted versus clot time (in seconds) for each sample mixture. In this series of studies, an identical amount (about one microgram) of soluble thrombomodulin was added to each assay cup. The filled circles (●) identify the protein C curve, and the open circles (○) identify the protein S curve. The point identified by the open triangle (Δ) marks the clot time of a mixture of 50% S-deficient and 50% C-deficient plasma.

FIGURE 3 shows the results of a coagulometric assay in which protein S functional activity was determined in a normal plasma sample. The concentration of normal plasma added to a protein S-deficient plasma sample is plotted versus clot time

(in seconds) for each sample mixture. In contrast to the data in FIGURE 2, the amount of thrombomodulin used in these assays was about 2 micrograms (instead of about 1 microgram) to determine if higher thrombomodulin levels would make the protein S functional assay more sensitive, and therefore more useful, for determining protein S functional activity.

FIGURE 4 shows the data from a coagulometric assay in which protein S functional activity was determined in a normal plasma sample to which pure *in vitro*-activated protein C, but not soluble thrombomodulin, was added at the beginning of the assay. The concentration of normal plasma added to a protein S-deficient plasma sample is plotted versus clot time (in seconds) for each sample mixture.

15

DETAILED DESCRIPTION OF THE PRESENT INVENTION

Novel one-stage coagulometric assay of the present invention.

20 The following is a detailed description of the novel assay of the present invention useful for directly determining in a plasma sample the functional activities of the vitamin K-dependent coagulation-inhibiting proteins, protein S and protein C. Also provided are descriptions of the necessary reagents and 25 instrumentation used in a preferred embodiment of the present invention. The invention takes advantage of the kinetic environment of an *in vitro* coagulometric assay to detect the

thrombin-mediated coagulation-inhibiting activity of protein C and protein S, and does so, in a preferred embodiment, in an assay in which all of the clotting factors of the intrinsic (in contradistinction to the extrinsic) coagulation pathway are involved, including clotting factors V and Va, and VIII and VIIIa.

Plasma specimen collection and preparation. In preparing plasma specimens for analysis in the coagulometric assay of the present invention, nine parts of freshly-collected patient blood are mixed thoroughly with one part of 3.8% sodium citrate anticoagulant. The anticoagulated blood specimen is then centrifuged for a minimum of 10 minutes at 1000 x G to pellet the large cellular components of the blood. The supernatant plasma is removed to a plastic tube, stoppered, and refrigerated at 4-6°C until used. Patient plasma is tested within two hours of blood collection to ensure validity and reproducibility of results, and is never held at 37°C for more than five minutes. Human plasma prepared in a similar manner can also be obtained from American Red Cross blood centers.

Coagulation-activating substance. In performing the coagulometric assay of the present invention, the preferred reagent for use in initiating coagulation in the assay cup is the "DADE®/ACTIN® ACTIVATED CEPHALOPLASTIN REAGENT", commercially supplied by Baxter Healthcare Corporation (Miami, FL), and described in the Baxter Healthcare Corporation package

insert No. L10293-BH-H (revised 10/88). The active ingredients in this commercial reagent are the negatively-charged organic compound, ellagic acid, and the phospholipid, cephalin, extracted from dehydrated rabbit brain. Use of soybean 5 phospholipid (lecithin) in place of cephalin did not give commercially adaptable results.

Other Reagents used in the one-stage coagulometric assay.

The following reagents are also required for use in the 10 one-stage coagulometric assay of the present invention:

- 1) saline, prepared as a 0.9% sodium chloride solution in water;
- 2) soluble thrombomodulin, isolated from rabbit lung tissue and purified according to the procedures of 15 Esmon & Owen (Proc. Natl. Acad. Sci. USA 78: 2249, 1981), and prepared in buffered saline at a final concentration appropriate to the assay; and
- 3) calcium chloride, prepared as a 25 millimolar solution in water.

20

The crucial feature of the assay of this invention is the use of soluble thrombomodulin as an additive to the coagulation reaction mixture. The use of soluble thrombomodulin for the activation of protein C in an *in vitro* coagulometric assay is 25 believed to be unique. When added to the other reagents in the reaction mixture, soluble thrombomodulin provides a highly reactive substrate for the subsequent high-affinity binding of

free thrombin. In the presence of calcium, the thrombin in the thrombin-thrombomodulin complex then activates protein C, which, together with protein S, degrades the clot-promoting factors Va and VIIIa in the plasma. Thus, using soluble thrombomodulin 5 anticoagulant as one of the assay reagents, and using protein C- and protein S-deficient plasma samples as deficient plasma controls, the coagulation-inhibiting activities of protein C and protein S can be directly determined in a novel one-stage assay procedure.

10

As noted above, the coagulometric assay of this invention for protein C and/or protein S is a one-stage assay because the assay is characterized by a single incubation. In contrast the prior art assays for protein C activate protein C during a 15 prior preactivation step, followed by an incubation to detect the activated protein C formed, and, thus, constitute ~~a~~ two-stage assays. Exemplary is the use of copperhead snake venom or "PROTAC-C", discussed above.

20

In one embodiment of this invention, the active ingredients and other reagents and controls of this invention constitute the components of a commercial assay kit for determining the functional status of vitamin K-dependent coagulation-inhibiting proteins, namely, protein C and protein S. For example, in 25 addition to the soluble thrombomodulin and the coagulation-activating agent of this invention, such a kit optionally contains one or more components selected from (i) a positive

control, e.g., a normal plasma sample, (ii) a negative control, e.g., protein C and/or protein S deficient plasma samples, and (iii) a buffered solution containing a calcium salt, e.g., calcium chloride.

5

Instrumentation used. In a preferred embodiment of the present invention, a Fibrometer™ coagulation timer (Becton, Dickinson and Company Rutherford, NJ) is used to determine the clot time in the coagulometric assay. When the Fibrometer™ is used, the probes must be thoroughly washed with distilled water and wiped dry with lint-free tissue between tests to prevent carryover of activated plasma proteins. Since there are two different types of probes available for this instrument, a 0.3-ml probe and a 0.4-ml probe, it is necessary to design the assay so that the final volume of reagents added to the reaction cups matches the requirements of the probe which is used.

Coagulation controls. With each series of tests, standard clot time curves are prepared using several control plasma samples in order to ensure the quality, reproducibility and interpretability of the data obtained. The control plasma samples are run in the same manner as the test samples, and establish a range of allowable variation for the control clot time values.

25

In the present invention, protein C-deficient and protein S-deficient plasma samples, used as factor-deficient plasma

controls, were prepared by immunoabsorption of different batches of the same citrated human plasma. Immunoabsorption was carried out using immobilized polyclonal antibodies. For example, to prepare protein C-deficient plasma, one volume of the citrated plasma was mixed in a batch preparation immunoabsorption procedure with nine volumes of anti-protein C coupled to Sepharose®. In contrast, to prepare protein S-deficient plasma, plasma was passed over a polyclonal antibody-Sepharose® affinity column, in a chromatography process well known in the art.

10 Regardless of the immunoabsorption method used, however, it must be noted that the concentration of factors V and VIII may be altered during the processing. Since these factors are crucial in the clotting cascade and are the principal protein targets of activated protein C and protein S as described earlier,

15 alterations in their concentrations will affect the coagulability of and the outcome of assays using the processed plasma samples. Accordingly, the concentrations of factors V and VIII in processed plasma samples must be standardized following immuno-absorption.

20

Assay Results. The results obtained in the coagulometric assays of the present invention are reported in seconds, and are related to a "normal range" of clot time values obtained in each laboratory. This normal range is established by obtaining

25 plasma samples from a large number of normal healthy donors (for example, from 25 to 40 individuals), and determining the range of statistically common clot time values for these normal donors

when tested in the same laboratory. The number of donors needed to establish a statistically acceptable range is determined by each laboratory. Blood is collected by the same method used for collecting test samples from patients, and clot times, using the 5 assay of the present invention, are determined on each normal citrated plasma.

In like manner, a range of values common to populations other than normal, healthy adults is also established as 10 warranted. For example, it may be of interest to establish normal ranges in selected age groups such as pediatric groups or the elderly; or in certain risk groups such as smokers, alcoholics, or individuals on certain medications.

15 The following examples demonstrate methods and describe protocols useful in practicing the present invention.

EXAMPLE 1.A one-stage functional assay of protein C in normal plasma.

In these studies, a Becton-Dickinson Fibrometer™ with a 0.4-ml probe was used. The following reagents were placed into 5 a coagulation cup, with care to add them quickly but accurately:

- a) 0.1 ml of the "DADE®/ ACTIN® ACTIVATED CEPHALOPLASTIN REAGENT" (as described hereinabove);
- b) 0.1 ml of normal plasma or protein C-deficient plasma.

10 As soon as these reagents were added into the cup, a timer was started, the reagents were mixed well, and incubated at 37°C for exactly 90 seconds. During this brief incubation time, the calcium-independent preactivation of the intrinsic coagulation cascade begins, with the activation of factor XII by kallikrein 15 on negatively charged surfaces, forming factor XIIa, an enzyme which catalyzes the conversion of factor XI, a proenzyme, to its active enzyme form, factor XIa. The rapid preactivation process stops here, in the absence of added calcium ions. At 90 seconds, the following were then added:

- 20 c) from 1 to 10 microliters of soluble thrombomodulin (equivalent to 0.1 to 1 micrograms of soluble thrombomodulin, respectively);
- d) sufficient volume of prewarmed (37°C) saline to bring the volume to 0.1 ml;
- 25 e) 0.1 ml of prewarmed 25mM CaCl₂.

The total volume in the coagulation cup was 400 microliters. Precisely as the calcium chloride was added, the Fibrometer™ timer and probes started automatically. The elapsed time until detection of a fibrin clot was determined automatically by the instrument. The indicated clot time was recorded for each assay cup in a replicate group.

The amount of soluble thrombomodulin added to the coagulometric assay was important. As shown in TABLE 1, the anticoagulant effect of soluble thrombomodulin in the presence of normal control plasma increased in direct proportion to the amount of thrombomodulin added to the assay. The control assay cup which contained only dialyzing buffer, and which lacked thrombomodulin, clotted in 30.4 seconds, whereas the addition of 1 microgram of soluble thrombomodulin increased this clot time more than five fold.

TABLE 1. Clot time (seconds) in coagulometric assay containing different amounts of soluble thrombomodulin.

Thrombomodulin (micrograms)	<u>Clot time (seconds)</u>	
	Control Plasma	*Deficient Plasma
0.1	37.9	
0.2	43.9	
0.6	69.8	64.8
0.8	112.9	71.8
1.0	156.9	81.3
buffer only	30.4	

*Plasma was deficient in protein C

These data also demonstrate that soluble thrombomodulin had a significantly different anticoagulant effect on protein C-deficient plasma than it did on normal control plasma. When these same data were plotted as amount of soluble thrombomodulin added (in micrograms) versus clot time (in seconds), two very different clot time lines were obtained, as shown in FIGURE 1.

It is important at this point to realize that the principal difference between the two plasma samples in this test was the presence of functional protein C molecules in the normal plasma sample compared to the absence of these molecules in the protein C-deficient plasma sample. Thus, the difference in slope of the two lines in FIGURE 1 reflects primarily the presence or absence of this coagulation-inhibiting protein.

15

Since soluble thrombomodulin exerts dual anticoagulant functions (one being its heparin-like effect which prevents thrombin from converting fibrinogen into fibrin; and the other being its role in converting protein C into activated protein C, which then degrades factors Va and VIIIa in the coagulation cascade), the clot time curve associated with the protein C-deficient plasma is a reflection solely of the heparin-like activity of thrombomodulin. In contrast, the clot time curve of the normal plasma is a reflection of the combination of the heparin-like activity of thrombomodulin and its protein C activating capacity. Hence, the difference in the clot times between the two curves in FIGURE 1 is a novel and simple way to

demonstrate and quantify the functional presence of protein C in the normal plasma sample.

5

EXAMPLE 2Sensitivity of the one-stage coagulometric assay for determining protein S and protein C functional deficiencies in plasma.

A one-stage functional assay of both protein C and protein S was set up essentially the same as in EXAMPLE 1, except that
10 a) a constant amount (1 microgram) of soluble thrombomodulin was added to each assay cup; and b) the normal and deficient plasma samples were mixed together in varying proportions, in a final volume of 100 microliters, to create a series of plasma test samples with different levels of protein C or protein S, from
15 100% down to 0% of normal. The normal control plasma had full protein C and protein S activity.

The results from these experiments are shown in FIGURE 2, in which the filled circles (●) identify the protein C curve,
20 and the open circles (○) identify the protein S curve. The point identified by the open triangle (Δ) marks the clot time of a mixture of 50% S-deficient and 50% C-deficient plasma.

The clot time curves for the protein C- and protein S-deficient plasma types were substantially different, as shown.
25 Bearing in mind that the part of an assay dilution curve wherein the assay is most sensitive to a change in the concentration of

the measured protein is the region comprising the steepest part of the curve, it is clear that the relative dilutions of protein C- or protein S-deficient plasma at which the coagulometric assays are most sensitive for those factors are substantially different. As shown in FIGURE 2, the clot time curve using protein C-deficient plasma is steeper (and therefore more sensitive) in the range of 50% or greater normal plasma than it is in the range of 0 to 50% normal plasma. In contrast, the protein S clotting curve is much steeper (and therefore more sensitive) in the range of from 0 to 25% normal plasma.

These data indicate that:

- a) assays to detect protein S functional deficiencies can be satisfactorily performed using dilute preparations of the patient plasma test sample (i.e., small volumes of test plasma relative to the volume of protein-S deficient plasma); and that
- b) under the same reaction conditions (i.e., about 1 microgram of thrombomodulin in the assay), assays for the sensitive detection of protein C functional deficiencies can be performed using small amounts of protein C-deficient plasma mixed into the test plasma sample.

In a more practical application of the present invention, these data also indicate that, under the same reaction conditions outlined above (i.e., approximately 1 microgram of

thrombomodulin in the assay), assays to detect protein C functional deficiencies permit significantly smaller amounts of protein C-deficient plasma to be mixed into the test plasma sample (i.e. cannot be carried out satisfactorily on dilute 5 preparations of the patient plasma test sample if the diluent is protein C-deficient plasma). Under these conditions, protein C in small amounts of test plasma may be satisfactorily measured by admixture with normal control plasma, thus taking advantage of the sensitive range of protein C detection shown in FIGURE 2.

10

In an effort to improve the sensitivity with which protein S functional deficiencies could be detected, the amount of soluble thrombomodulin in the coagulometric assay of the present invention was raised from 1 microgram (as used above in EXAMPLE 15 2) to 2 micrograms, as shown in the following example.

EXAMPLE 3

Use of higher concentrations of soluble thrombomodulin 20 to determine protein S function

Doubling (to 2 micrograms) the amount of soluble thrombomodulin reagent added to the coagulometric assay made the assay more sensitive to determining protein S functional activity. As shown in FIGURE 3, a substantial range of clot 25 times (from approximately 90 seconds to 200 seconds; a range of about 110 seconds) was observed when protein S was assayed at concentrations varying from 0% (equivalent to 100% protein S-

deficient plasma) to 25% of normal (equivalent to 3 parts protein S-deficient plasma to 1 part normal plasma). Thus, by adding about 2 micrograms of soluble thrombomodulin to the assay system, the assay became substantially more sensitive to protein S in the test samples than was detected using only 1 microgram of soluble thrombomodulin. Therefore, the sensitivity with which protein S functional deficiencies in plasma are detected is dependent on the concentration of thrombomodulin used in the assay.

10

It was important to compare these results with those of an assay for protein S based on adding exogenous, preactivated protein C into a coagulometric assay. The following example demonstrates that, in the absence of soluble thrombomodulin, the 15 results were substantially different and were not as useful as the results obtained from assays which incorporated soluble thrombomodulin.

20

EXAMPLE 4Adding activated protein C instead of soluble thrombomodulin to a coagulometric assay for protein S

The data in FIGURE 4 were obtained in an assay which utilized activated protein C, but not soluble thrombomodulin, as 25 a coagulation-inhibiting protein factor. In a Fibrometer™ coagulation cup, the following were added:

- a) 0.1 ml of "DADE®/ACTIN® ACTIVATED CEPHALOPLASTIN REAGENT" described in detail above;
 - b) 0.1 ml of plasma; and
 - c) 0.4 micrograms of activated protein C.
- 5 These reagents were incubated at 37°C for exactly 90 seconds, at which time 0.1 ml of saline was added, followed immediately by 0.1 ml of calcium chloride, activating the clotting reaction and the instrument timer.

10.

The data show that the range in clot time (from approximately 54 seconds with undiluted protein S-deficient plasma, to about 89 seconds with 75% protein S-deficient plasma; a range of only about 35 seconds) was approximately one-third of the range in clot time shown in FIGURE 3 in the previous example. Because the change in reagents reduced the range of assay responses by nearly 67%, it is clear that adding activated protein C instead of soluble thrombomodulin into the coagulometric assay did not provide as useful a measure of protein S function as was found in the coagulometric assay of the previous examples.

It will be appreciated that changes may be made in the nature, composition, operation and arrangement of the various 25 elements, steps and procedures described herein without departing from the spirit and scope of the invention as defined in the following claims.

WHAT IS CLAIMED IS:

- 1 1. A one-stage blood coagulation assay for directly
2 determining the functional status of vitamin K-dependent
3 coagulation-inhibiting proteins in plasma, said method comprising
4 combining a blood plasma test sample and a coagulation-activating
5 substance in a calcium-free solution, then adding soluble
6 thrombomodulin and calcium ions to the resultant mixture to
7 initiate a coagulation reaction, measuring the time required for
8 said test plasma sample to clot, comparing the measured clot time
9 to that of standard control plasma samples, and then using the
10 compared clot time values for determining the risk of thrombosis
11 in the individual from whom said plasma test sample was taken.

- 1 2. The method of claim 1 wherein said vitamin K-dependent
2 coagulation-inhibiting protein is selected from the group
3 consisting of protein C and protein S.

- 1 3. The method of claim 1 wherein said vitamin K-dependent
2 coagulation-inhibiting protein is protein S.

- 1 4. The method of claim 1 wherein said blood plasma test
2 sample is obtained from a human donor.

- 1 5. The method of claim 4 wherein said human donor is a
2 clinical subject.

1 6. The method of claim 1 wherein said coagulation-
2 activating substance is a negatively charged organic molecule.

1 7. The method of claim 6 wherein said negatively charged
2 molecule is ellagic acid.

1 8. The method of claim 1 wherein said coagulation-
2 activating substance is tissue factor.

1 9. The method of claim 1 wherein said coagulation-
2 activating substance is factor Xa.

1 10. The method of claim 1 wherein said coagulation-
2 activating substance is Russell's viper venom.

1 11. The method of claim 1 wherein said standard control
2 plasma samples are normal control plasma samples, derived from
3 one or more normal healthy donors, and which contain
4 statistically-common and expected amounts of all known
5 coagulation-related factors.

1 12. The method of claim 1 wherein at least one of said
2 standard control plasma samples is selected from the group
3 consisting of a protein C-deficient plasma sample and a protein
4 S-deficient plasma sample.

1 13. The method of claim 1 wherein at least one of said
2 standard control plasma samples is a protein S-deficient plasma
3 sample.

1 14. A soluble complex comprising activated protein C and
2 protein S bound to a soluble micelle-forming or liposome-forming
3 surface, said surface being amphipathic and having a charge
4 distribution and size suitable for binding said protein C and
5 said protein S.

6

1 15. A soluble complex comprising soluble thrombomodulin,
2 thrombin and protein C, bound to the surface of claim 14.

3

4 16. The complex of claim 15 wherein said surface is a
5 soluble phospholipid surface.

6

1 17. A soluble complex comprising activated protein C and
protein S, bound to a soluble phospholipid surface.

1 18. A soluble complex comprising activated protein C,
protein S and factor Va, bound to a soluble phospholipid surface.

1 19. A soluble complex comprising activated protein C,
protein S and factor VIIIa, bound to a soluble phospholipid
3 surface.

1. 20. The soluble complex of claims 16, 17, 18 and 19
2 wherein said phospholipid is a cephalin derived from rabbit brain
3 tissue.
1. 21. The method of claim 1, wherein said vitamin K-dependent
2 coagulation inhibiting protein is protein C
1. 22. The method of claim 1 wherein at least 1 of said
2 standard control plasma samples is a protein C-deficient
3 plasma sample




FIGURE 1

FIGURE 2

corrected FIG. 2 (9/11)

(and corrected DS)

Chesapeake 1985
Date 5/31/91

Seconds

180

160

140

120

100

80

25

50

75

100

% OF NORMAL

100%
(normal controls)
plasma

0.149

0.158

0.159

0.186

0.173

0.109

0.110

0.101

80

100

120

140

160

180

200

220

240

260

280

300

320

340

360

380

400

420

440

460

480

500

520

540

560

580

600

620

640

660

680

700

720

740

760

780

800

820

840

860

880

900

920

940

960

980

1000

1020

1040

1060

1080

1100

1120

1140

1160

1180

1200

1220

1240

1260

1280

1300

1320

1340

1360

1380

1400

1420

1440

1460

1480

1500

1520

1540

1560

1580

1600

1620

1640

1660

1680

1700

1720

1740

1760

1780

1800

1820

1840

1860

1880

1900

1920

1940

1960

1980

2000

2020

2040

2060

2080

2100

2120

2140

2160

2180

2200

2220

2240

2260

2280

2300

2320

2340

2360

2380

2400

2420

2440

2460

2480

2500

2520

2540

2560

2580

2600

2620

2640

2660

2680

2700

2720

2740

2760

2780

2800

2820

2840

2860

2880

2900

2920

2940

2960

2980

3000

3020

3040

3060

3080

3100

3120

3140

3160

3180

3200

3220

3240

3260

3280

3300

3320

3340

3360

3380

3400

3420

3440

3460

3480

3500

3520

3540

3560

3580

3600

3620

3640

3660

3680

3700

3720

3740

3760

3780

3800

3820

3840

3860

3880

3900

3920

3940

3960

3980

4000

4020

4040

4060

4080

4100

4120

4140

4160

4180

4200

4220

4240

4260

4280

4300

4320

4340

4360

4380





FIGURE 4



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US92/08389

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) :G01N 33/68; G01N 33/00; C07K 15/06; C12Q 1/56

US CL :435/13, 183, 172.3, 7.92, 24, 86; 536/27; 435/69; 514/21, 2, 8, 2

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/13, 183, 172.3, 7.92, 24, 86; 536/27; 435/69; 514/21, 2, 8, 2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS (vit k-dependent) (coagulation, inhibiting protein, protein c, protein s, ellagic acid, factor Xa).

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A, 5,001,069 (Bartl et al) 19 March 1991, ENTIRE DOCUMENT.	1-22
Y	US, A, 4,849,403 (Stocker et al) 18 July 1989, ENTIRE DOCUMENT.	1-22
Y	US, A, 5,051,357 (Hassouna) 24 September 1991, ENTIRE DOCUMENT.	1-22
Y	US, A, 4,736,018 (Reutelingsperger) 05 April 1988, ENTIRE DOCUMENT.	1-22
A	US, A, 4,748,156 (Aoki et al) 31 May 1988.	1-22
Y	Blood, Volume 71(4), issued April 1988, Faioni et al, "Isolation of an abnormal protein C molecule from the plasma of a patient with thrombotic diathesis", pages 940-946. See entire document.	1-22

 Further documents are listed in the continuation of Box C.

See patent family annex.

• Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
•A• document defining the general state of the art which is not considered to be part of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
•E• earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
•L• document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
•O• document referring to an oral disclosure, use, exhibition or other means		
•P• document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

21 DECEMBER 1992

Date of mailing of the international search report

08 JAN 1993

Name and mailing address of the ISA/
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Authorized officer

EXAMINER LEARY ROZ

Telephone No. (703) 308-0196

Facsimile No. NOT APPLICABLE

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.